Pharma networker

Pharma networker

17.10.2014 - Jarrod Longcor the former Vice President of Corporate Development for Rib-X Pharmaceuticals has been appointed CBO at Avillion LLP.

Jarrod Longcor brings over 18 years of pharmaceutical and biotech experience to the London-based drug development company. In his previous role at Rib-X Pharmaceuticals, Inc (now Melinta Therapeutics), Longcor was responsible for identifying and concluding several critical collaborations for the company. Prior to Rib-X, he held key positions in several small to mid-sized biotech companies where he was responsible for business development and strategic planning. At Avillion, Longcor will be responsible for structuring, negotiating and executing strategic alliances, co-development agreements, and financial instruments, as well as providing management and strategic leadership to the organisation.

08.04.2014 Germany’s Merck KGaA (Darmstadt) has hired the former head of Boehringer Ingelheim’s biopharmaceuticals development team to lead its biosimilar unit, which was set up in 2012.


Prior to the stint at Boehringer, Simon Sturge was CEO of Dutch biotech OctoPlus NV, and he also acted as CEO of Vernalis plc (UK). In the past, Sturge has held several roles of increasing seniority – from Business Development, Marketing and Operations to CEO at Lonza Biologics, as well as at Celltech Biologics and at AstraZeneca. The native of Britain was awarded the UK Mediscience CEO of the Year award in 2005. Sturge succeeds Thierry Hulot, who created Merck’s biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of 2013. Along with Sturge, Merck has also strengthened its team internally with Friederike Rotsch, who has now taken over as chief legal advisor. 

27.03.2014 Ghent-based AgroSavfe BV has added to its management team Maria Abad-Molina new Head of Product & Business Development and Dr. Miguel De Bolle (Photo) as Head of Research.


While Bolle will head R&D to advance the company's Agrobody-technology platform for the development of innovative formulations for the sustainable use of crop protection products, Abad-Molina will be responsible for product development and registration at the company. A trained agronomical engineer who holds an Executive MBA, Abad--Molina has more than 20 years of experience in the crop protection and plant biotech-nology industries. Before joining the AgroSavfe management team, she was on the management team of BASF Plant Science subsidiary CropDesign, where she led global activities for placing plant protection products in the market, including the firm's top herbicide in terms of sales.

25.03.2014 British late-stage drug co-developer Avillion LLP appointed Dr. Allison Jeynes-Ellis to the post of Chief Executive Officer in February.

Dianna Bonner

The company’s cofounder and former CMO previously worked in senior roles at various pharmaceutical companies, including Wyeth, Bristol-Myers Squibb and Novartis. She has also acted as an independent consultant to many companies – including CAT and Genentech – as well as government bodies and medical research charities.

20.03.2014 In-vitro diagnostics instrumentation and software specialist Stratec Bio-medical AG (Birkenfeld) has appointed Claus Vielsack to its management board as Product Development Director.

Stratec Biomedical

Vielsack (46) has held various senior product development positions at Stratec since 1998. Before joining the Dx specialist, he held a number of different positions working as a programme manager in the development of chemical applications and software solutions.

18.03.2014 The European Medicines Agency (London) has named Dina Tsiambaou to head its IT Development Department.


She joins the Agency from Accenture, where she has had a long career defining, leading and delivering complex IT transformation and implementation projects. As with all EMA staff members, Tsiambaou will have to declare her interests in the pharmaceutical industry and divest herself of any shares she might own in pharmaceutical companies before beginning work at the Agency.

14.03.2014 Sartorius AG (Göttingen) has tapped the former CEO of analytical instruments provider Methrom’s US division to head marketing, sales and services at the firm’s Lab Products & Services Division.

Sartorius AG

Michael Melingo succeeds Dominique Baly, who is retiring. The new member of the Executive Committee – the highest operational management level in the Sartorius Group – brings in more than 30 years of experience in the industry. Prior to Methrom, the bioengineer worked as a sales and marketing executive with Baxter, Bio-Rad, Millipore and Waters in Europe and Asia.

12.03.2014 Medical device developer Vexxim SA (Toulouse) has named Sandrine Carle (43) to the post of Marketing Director.


Carle, who came in from Medtronics, will be responsible for the expansion of Vexxim’s business in new international markets. After graduating with a Master’s in Biomedical Engineering from Compiègne University of Technology (France) in 1994, she began her industry carreer at Aescula. In 2013, she obtained an Executive MBA from HEC Paris.

06.03.2014 Kemal Malik (51) has been appointed to the Board of Bayer AG.

Bayer AG

Malik has been a member of the Bayer HealthCare Executive Committee and its Head of Global Development and Chief Medical Officer since 2007. He is to succeed Prof. Wolfgang Plischke, who is retiring. In his new position, Malik will be responsible for innovation, and is taking over responsibility for the North America region. Before joining Bayer in 1995, the physician held various positions of increasing responsibility at Bristol-Myers Squibb. At Bayer, he served as Head of Global Medical Development before being appointed Head of Global Development.

03.03.2014 Robert Cascella has joined Edinburgh-based DySIS Medical as Chairman of its board.

DySIS Medical

He joins the medical devices company from diagnostics firm Hologic Inc. where Cascella was Chief Executive Officer. Prior to Hologic, the expert from the women’s healthcare industry served as a Managing Partner of the investment banking firm CFG Capital LLC, and also had a stint as the Chief Operating Officer and Vice President of Finance at NeoVision Corporation.

28.02.2014 Enzyme manufacturer Royal DSM and Roquette Frères joint-venture Reverdia named a new president at the beginning of 2014.

Marcel Lubben, who steps in for former General Manager Will van den Tweel, will be responsible for pushing growth in the emerging market for sustainably produced bio-based succinic acid. The new appointee certainly appears to have the commercial and business leadership experience required for that challenge. Lubben held positions in Research, Business Development and Marketing & Sales in DSM Pharma Chemicals and DSM Biologics before transitioning into the industrial biotech­nology sector. In 2009, he was appointed Managing Director Licensing for DSM, and became Managing Director Venturing & Licensing in 2011. In 2012 he became Vice President Bio-based Chemicals & Materials. The new President also served as a member of the Reverdia board from mid-2012 until the end of 2013.

Vorherige Seite5/21Nächste Seite

Print Magazine

Event Video

All videos


All Events

Stock list

All quotes


  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%


  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%


  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%


  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%


  • SANTHERA82.40 CHF2139.1%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR141.3%


  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.6%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 19.10.2014

Current issue

All issues

Product of the week